

# APPLICATIONS

## Exploring the Effect of Mobile Phase Concentration on Sensitivity of Size Exclusion-Mass Spec (SEC-MS) for Monoclonal Antibodies using a bioZen™ SEC-3 Column

M. Christina Malinao and Helen Whitby Ph.D.  
Phenomenex, Inc., 411 Madrid Ave., Torrance, CA 90501

### Overview

In recent years the trend of drug design and development has switched from small molecule targets to biotherapeutics as the next generation of therapies in order to address the short comings of the small molecules. Monoclonal antibody (mAb) aggregates are one significant class of these large molecules that have significant implications in safety, immunogenicity, and efficacy for therapeutic drug development. Size exclusion chromatography (SEC) is one of the laboratory methods used to determine the extent of aggregation of a protein, a critical quality attribute required for all therapeutic mAbs. In addition, SEC can detect low molecular weight (LMW) species including protein fragments. Native mass spectrometry (MS) using electrospray ionization allows proteins to be analyzed in non-denaturing volatile buffers. When this is done using controlled pH, ionic strength and ionization the conformation of the protein in the solution phase is maintained to allow it to remain intact during transmission into the gas phase. The use of intact native MS is an important technique to study non-covalent protein interactions, including those observed in reversible aggregate species.


In this application note we look at the impact that mobile phase concentration has on the sensitivity of SEC-MS when used to analyze intact mAb's under non-denaturing conditions. The SEC analysis of Trastuzumab is used to demonstrate the loss in MS sensitivity when working at high buffer concentrations.

Trastuzumab was analyzed using the bioZen 1.8 µm SEC-3, 300Å column with an ammonium acetate mobile phase. Higher resolution of the monomer and dimer peaks can be achieved using a higher concentration buffer of 100mM however this resulted in lower sensitivity of the mass spec data. When working at 50 mM, the signal from the mass spec was found to be significantly higher but this was at the expense of resolution and separation of the monomer from dimer were compromised due to significant peak broadening. Overall, care should be taken to balance mobile phase formulation to maximize mass spec sensitivity while maintaining chromatographic performance.


### LC Conditions

**Column:** bioZen 1.8 µm SEC-3  
**Dimension:** 50 x 2.1 mm  
**Part No.:** [00B-4772-AN](#)  
**Recommended Guard:** SecurityGuard™ ULTRA  
**Guard Cartridge Part No.:** [AJ0-9851](#)  
**Guard Holder Part No.:** [AJ0-9000](#)  
**Mobile Phase:** A: 50 mM Ammonium Acetate  
B: 100 mM Ammonium Acetate  
**Flow Rate:** 50 µL/min  
**Temperature:** 25 °C  
**Detector:** QTOF (SCIEX® X500B)  
**Sample:** Trastuzumab


### DAD-280 nm Trastuzumab



App ID: 25583



App ID: 25583



App ID: 25583

# APPLICATIONS

## Need a different column size or sample preparation format?

No problem! We have a majority of our available dimensions up on [www.phenomenex.com](http://www.phenomenex.com), but if you can't find what you need right away, our super helpful Technical Specialists can guide you to the solution via our online chat portal [www.phenomenex.com/LiveChat](http://www.phenomenex.com/LiveChat).

### Australia

t: +61 (0)2-9428-6444  
auiinfo@phenomenex.com

### Austria

t: +43 (0)1-319-1301  
anfrage@phenomenex.com

### Belgium

t: +32 (0)2 503 4015 (French)  
t: +32 (0)2 511 8666 (Dutch)  
beinfo@phenomenex.com

### Canada

t: +1 (800) 543-3681  
info@phenomenex.com

### China

t: +86 400-606-8099  
cninfo@phenomenex.com

### Denmark

t: +45 4824 8048  
nordicinfo@phenomenex.com

### Finland

t: +358 (0)9 4789 0063  
nordicinfo@phenomenex.com

### France

t: +33 (0)1 30 09 21 10  
franceinfo@phenomenex.com

### Germany

t: +49 (0)6021-58830-0  
anfrage@phenomenex.com

### India

t: +91 (0)40-3012 2400  
indiainfo@phenomenex.com

### Ireland

t: +353 (0)1 247 5405  
eirinfo@phenomenex.com

### Italy

t: +39 051 6327511  
italiainfo@phenomenex.com

### Luxembourg

t: +31 (0)30-2418700  
nlinfo@phenomenex.com

### Mexico

t: 01-800-844-5226  
tecnicomx@phenomenex.com

### The Netherlands

t: +31 (0)30-2418700  
nlinfo@phenomenex.com

### New Zealand

t: +64 (0)9-4780951  
nzinfo@phenomenex.com

### Norway

t: +47 810 02 005  
nordicinfo@phenomenex.com

### Portugal

t: +351 221 450 488  
ptinfo@phenomenex.com

### Singapore

t: +65 800-852-3944  
sginfo@phenomenex.com

### Spain

t: +34 91-413-8613  
espinfo@phenomenex.com

### Sweden

t: +46 (0)8 611 6950  
nordicinfo@phenomenex.com

### Switzerland

t: +41 (0)61 692 20 20  
swissinfo@phenomenex.com

### Taiwan

t: +886 (0) 0801-49-1246  
twinfo@phenomenex.com

### United Kingdom

t: +44 (0)1625-501367  
ukinfo@phenomenex.com

### USA

t: +1 (310) 212-0555  
info@phenomenex.com

### All other countries Corporate Office USA

t: +1 (310) 212-0555  
info@phenomenex.com

## [www.phenomenex.com](http://www.phenomenex.com)

Phenomenex products are available worldwide. For the distributor in your country, contact Phenomenex USA, International Department at [international@phenomenex.com](mailto:international@phenomenex.com)

### Terms and Conditions

Subject to Phenomenex Standard Terms and Conditions, which may be viewed at [www.phenomenex.com/TermsAndConditions](http://www.phenomenex.com/TermsAndConditions).

### Trademarks

bioZen is a trademark of Phenomenex. Sciex is a registered trademark of AB Sciex Pte. Ltd. AB SCIEX™ is being used under license.

FOR RESEARCH USE ONLY. Not for use in clinical diagnostic procedures.

© 2019 Phenomenex, Inc. All rights reserved.